Home

Pertuzumab

Pertuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It binds to subdomain II of HER2 and prevents receptor dimerization with other members of the HER family, especially HER3, thereby inhibiting downstream signaling through pathways such as PI3K/AKT and MAPK. This mechanism complements other anti-HER2 therapies by blocking additional aspects of HER2-driven growth and facilitating antibody-dependent cellular cytotoxicity.

Clinically, pertuzumab is used in combination regimens for HER2-positive cancers. In the United States, it is

Administration and safety considerations include intravenous infusion, typically given every three weeks in combination regimens. Cardiac

approved
for
use
with
trastuzumab
and
a
taxane
as
initial
therapy
for
metastatic
HER2-positive
breast
cancer
and
for
neoadjuvant
treatment
of
HER2-positive
breast
cancer
to
increase
pathological
complete
response
rates.
It
is
also
approved
in
several
regions
for
first-line
treatment
of
HER2-positive
metastatic
gastric
or
gastroesophageal
junction
cancer
in
combination
with
trastuzumab
and
chemotherapy,
based
on
studies
showing
an
overall
survival
benefit
when
added
to
standard
therapy.
monitoring,
including
periodic
assessment
of
left
ventricular
ejection
fraction,
is
recommended
due
to
the
risk
of
cardiotoxicity.
Common
adverse
effects
can
include
diarrhea,
alopecia,
nausea,
fatigue,
and
infusion-related
reactions.
Pertuzumab
is
marketed
under
the
brand
name
Perjeta
and
was
developed
by
Genentech,
a
subsidiary
of
Roche.